Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation.

Mori H, Suzuki H, Matsuzaki J, Tsugawa H, Fukuhara S, Miyoshi S, Hirata K, Seino T, Matsushita M, Masaoka T, Kanai T.

Helicobacter. 2016 Aug;21(4):286-94. doi: 10.1111/hel.12286. Epub 2015 Nov 27.

PMID:
26612407
2.

Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan.

Hirata Y, Ohmae T, Yanai A, Sakitani K, Hayakawa Y, Yoshida S, Sugimoto T, Mitsuno Y, Akanuma M, Yamaji Y, Ogura K, Maeda S, Koike K.

Int J Antimicrob Agents. 2012 Apr;39(4):352-5. doi: 10.1016/j.ijantimicag.2011.12.002. Epub 2012 Feb 7.

PMID:
22321702
3.

Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan.

Sugimoto M, Sahara S, Ichikawa H, Kagami T, Ban H, Otsuka T, Andoh A, Furuta T.

Helicobacter. 2017 Feb;22(1). doi: 10.1111/hel.12319. Epub 2016 May 23.

PMID:
27213463
4.

Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.

Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, Sahara S, Ichikawa H, Yamada T, Osawa S, Sugimoto K, Watanabe H, Umemura K.

J Gastroenterol Hepatol. 2014 Mar;29(3):487-93. doi: 10.1111/jgh.12442.

PMID:
24224808
5.

10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy.

Mori H, Suzuki H, Matsuzaki J, Masaoka T, Kanai T.

Digestion. 2019 Aug 6:1-7. doi: 10.1159/000501610. [Epub ahead of print]

PMID:
31387107
6.

Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.

Matsuzaki J, Suzuki H, Nishizawa T, Hirata K, Tsugawa H, Saito Y, Okada S, Fukuhara S, Hibi T.

Antimicrob Agents Chemother. 2012 Mar;56(3):1643-5. doi: 10.1128/AAC.05941-11. Epub 2011 Dec 27.

7.

Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen.

Hirata Y, Serizawa T, Shichijo S, Suzuki N, Sakitani K, Hayakawa Y, Yamada A, Koike K.

Int J Infect Dis. 2016 Oct;51:66-69. doi: 10.1016/j.ijid.2016.08.019. Epub 2016 Aug 30.

8.

High Helicobacter pylori cure rate with sitafloxacin-based triple therapy.

Sugimoto M, Sahara S, Ichikawa H, Kagami T, Uotani T, Furuta T.

Aliment Pharmacol Ther. 2015 Aug;42(4):477-83. doi: 10.1111/apt.13280. Epub 2015 Jun 15.

9.

Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients.

Mori H, Suzuki H, Matsuzaki J, Masaoka T, Kanai T.

United European Gastroenterol J. 2017 Oct;5(6):796-804. doi: 10.1177/2050640616688995. Epub 2017 Jan 19.

10.

Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.

Sue S, Shibata W, Sasaki T, Kaneko H, Irie K, Kondo M, Maeda S.

J Gastroenterol Hepatol. 2019 Apr;34(4):686-692. doi: 10.1111/jgh.14456. Epub 2018 Sep 21.

PMID:
30151994
11.

Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial.

Liou JM, Chen CC, Chen MJ, Chang CY, Fang YJ, Lee JY, Sheng WH, Wang HP, Wu MS, Lin JT.

J Antimicrob Chemother. 2011 Aug;66(8):1847-52. doi: 10.1093/jac/dkr217. Epub 2011 May 31.

PMID:
21632579
12.

Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.

Nishizawa T, Suzuki H, Nakagawa I, Iwasaki E, Masaoka T, Hibi T.

J Gastroenterol Hepatol. 2008 Dec;23 Suppl 2:S167-70. doi: 10.1111/j.1440-1746.2008.05407.x.

PMID:
19120892
13.

Mutations of Helicobacter pylori associated with fluoroquinolone resistance in Korea.

Lee JW, Kim N, Nam RH, Park JH, Kim JM, Jung HC, Song IS.

Helicobacter. 2011 Aug;16(4):301-10. doi: 10.1111/j.1523-5378.2011.00840.x.

PMID:
21762270
14.

Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea.

Kang KK, Lee DH, Oh DH, Yoon H, Shin CM, Park YS, Kim N, Jung HC.

World J Gastroenterol. 2014 Jun 14;20(22):6932-8. doi: 10.3748/wjg.v20.i22.6932.

15.

Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.

Almeida N, Romãozinho JM, Donato MM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Sofia C.

Helicobacter. 2014 Apr;19(2):90-7. doi: 10.1111/hel.12106. Epub 2014 Feb 10.

PMID:
24506175
16.

Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.

Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS, Kim N.

World J Gastroenterol. 2015 May 14;21(18):5568-74. doi: 10.3748/wjg.v21.i18.5568.

17.

Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection.

Miehlke S, Krasz S, Schneider-Brachert W, Kuhlisch E, Berning M, Madisch A, Laass MW, Neumeyer M, Jebens C, Zekorn C, Knoth H, Vieth M, Stolte M, Lehn N, Morgner A.

Helicobacter. 2011 Dec;16(6):420-6. doi: 10.1111/j.1523-5378.2011.00867.x.

PMID:
22059392
19.
20.

Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication.

Di Caro S, Franceschi F, Mariani A, Thompson F, Raimondo D, Masci E, Testoni A, La Rocca E, Gasbarrini A.

Dig Liver Dis. 2009 Jul;41(7):480-5. doi: 10.1016/j.dld.2008.09.013. Epub 2008 Oct 30.

PMID:
18974025

Supplemental Content

Support Center